Note: Descriptions are shown in the official language in which they were submitted.
CA 02906552 2015-09-14
WO 2(114/16(1-15-1
PCT/US2014/026671
1
TITLE
METHODS FOR DIAGNOSING VITREO-RETINAL DISEASE
BACKGROUND OF THE INVENTION
[0001] The young, healthy vitreous is a homogeneous, optically transparent gel
filling the
posterior segment of the eye. Gel vitreous volume increases during the first
decade while
the eye is growing in size and then remains stable until about the age of 40
years, when it
begins to decrease in parallel with an increase in liquid vitreous.
Macromolecular
changes occurring during this process result in inhomogeneities within the
vitreous.
Concurrently, changes occurring at the vitreo-retinal interface allow the
posterior vitreous
cortex to detach from the internal ILL of the retina. When liquefaction and
dehiscence
occur simultaneously and in concert, the result is an innocuous posterior
vitreous
detachment (PVD). When the natural processes do not occur in concert, an
anomalous
PVD (APVD) may develop. The ability to diagnose precursors of APVD and to
differentiate normal changes in vitreous related to aging from abnormal
changes would
permit early intervention before vitreo-retinal diseases progress to an
advanced state. This
would have a significant clinical impact by decreasing the likelihood of
blindness, and
reducing the cost of treatment and the risk to patients associated with
advanced disease
states. More broadly, early diagnosis has the potential to impact therapeutics
of systemic
diseases of the body such as diabetes.
[0002] The most clinically significant vitreo-retinal disease is diabetic
retinopathy. The
increased glucose levels in the vitreous of diabetic subjects have been shown
to be
associated with increased nonenzymatic glycation products and elevated levels
of cross-
linking and aggregation of vitreous collagen fibrils. Alteration of the
vitreous due to poor
glycemic control can extend or contract the vitreous hyaluronan, induce an
APVD, and
predates by years the optically visible evidence of retinal disease such as
microhemorrhages, microaneurysms, leakage with hard exudates (detectable by
examination and photography), and edema or neovascularization (detectable by
fluorescein angiography). Unfortunately, because no current diagnostic
technology is
CA 02906552 2015-09-14
WO 2(114/16(1-15-1
PCT/US2014/026671
2
able to detect the precursors of diabetic retinopathy, the disease is
typically only detected
in the aforementioned advanced states at which point treatments are costly,
difficult to
implement, carry some risk to patient or may be too late to prevent blindness.
The ability
to detect and quantify the macromolecular and physiopathologic abnormalities
of the
vitreous much earlier in disease progression would permit better disease
management,
reduce ultimate treatment cost, and reduce the ultimate risk blindness.
[0003] Another vitreo-retinal disease affecting a significant number of
patients is high
myopia (exceeding -6 diopters), which has a 4% prevalence in the general
population.
Biochemical studies in myopic human eyes found a decreased collagen content
and
concentration in the central vitreous. The vitreous body in myopia becomes
liquefied and
contains filaments with localized nodules. The formation of liquid vitreous in
myopia
markedly destabilizes vitreous and threatens the retina because this process
occurs
relatively early in life and is not concurrent with dehiscence at the vitreo-
retinal interface.
This is different from the mechanism of vitreous liquefaction seen in aging,
wherein the
increase in liquid vitreous volume occurs in synchrony with decreased adhesion
of
vitreous to retina. The increased rate of liquefaction in high myopia leads to
an increased
incidence of PVD that typically occurs 5 to 10 years earlier than age-normal
subjects.
Myopic patients have a much greater risk of retinal detachment and, without
treatment,
blindness. A non-invasive diagnostic tool that does not require dilation that
is capable of
characterizing changes to the vitreous that signal a risk in a given
individual, would
permit early intervention.
[0004] Floaters are a common complaint related to myopia, PVD, and vitreous
liquefaction/collagen aggregation due to aging, inflammation, and diabetes.
Floaters
move with vitreous displacement during ocular saccades and scatter incident
light,
casting a shadow on the retina that is perceived as a hair-like structure. PVD
may also
induce a glare caused by light scattering from condensed vitreous fibers, the
detached
posterior vitreous cortex, glial tissue of epipapillary origin adherent to the
posterior
vitreous cortex, or intravitreal blood. However, nothing is known about the
size, number.
or location of floaters as they relate to disease progression and normal
aging.
CA 02906552 2015-09-14
WO 2(114/16(1-15-1
PCT/US2014/026671
3
[0005] To more effectively diagnose, treat, and ultimately prevent disorders
of the
vitreous, a rapid, safe, reproducible, and objective way to quantify the state
of
opacification (i.e., inhomogeneity) of the vitreous is needed. This approach
differs from
typical ophthalmic ultrasound devices that are designed to image the front or
back of the
eye rather than the vitreous. Because inhomogeneities within the vitreous are
non-
uniformly distributed, the method to quantify inhomogeneities would ideally
make use of
data obtained throughout the vitreous volume. Optical coherence tomography
(OCT)
permits visualization of abnormalities in the vicinity of the vitreo-retinal
interface, but
does not permit assessment of peripheral retinal pathology or imaging of the
sclera and
orbital tissues, nor does it allow assessment of motility of vitreous
membranes in
response to saccades, which is readily accomplished with real-time ultrasound.
Ultrasound permits visualization of the entire vitreous and is sensitive to
micro-scale (on
the order of 20 gm) tissue properties related to changes in mass density and
speed of
sound (e.g., liquefaction vs. normal vitreous) and particle size and particle
concentration
(e.g., collagen aggregation, cell migration and proliferation within certain
regions of the
vitreous body.
SUMMARY OF THE INVENTION
[0006] A quantitative approach to characterize vitreous inhomogeneities (i.e.,
changes in
acoustic impedance related to local properties and acoustic scatterers) in
terms of
contrast, size, shape and distribution is described. In one embodiment the
imaging
modality employed may be ultrasound, specifically ultrasound with high-
frequency, 20
MHz annular-array transducer. The methods could be translated to any imaging
modality
that provides image data with sufficient contrast within the vitreous. The
technique can
be applied to 2D image planes of the full globe in one embodiment, or 3D
volume data
that has been assembled from a series of 2D image planes. The methods provide
an
objective means of characterizing the vitreous and represents a tool for early
diagnosis,
monitoring and planning treatment of vitreo-retinal diseases. The final step
of the
invention delivers at least one global parameter related to vitreous
inhomogeneities and
the pathologic state of the imaged eye. The global parameter can be used to
diagnose
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
4
vitreous conditions ranging from normal to various stages of malady. The
diagnosis may
be arranged to identify health or malady based on age.
[0007] Standard ultrasound images (i.e., B-mode) are representations of
microstructure
variations in the acoustical impedance of tissue. The images are qualitative
because much
of the information content of the acoustic waves is not utilized when forming
B-mode
images and each operator is free to adjust system settings (e.g., time-gain
control, focus,
acoustic power, etc.) to what they consider ideal. A standard B-mode image is
formed by
displaying the log-compressed envelope of the phase-resolved signal which
removes the
phase information. The goal of quantitative ultrasound (QUS) methods is to
process raw,
phase- resolved backscatter data in a system- and user-independent fashion in
order to
derive, by definition, quantitative estimates of acoustical and tissue
properties.
[0008] Considerable research and development in QUS for biomedical
applications has
occurred over the past three decades. QUS methods to estimate speed of sound,
density,
attenuation, elastic properties of tissue, average scatterer size and acoustic
concentration,
and spectral parameters related to some defined bandwidth of the ultrasound
transducer,
such as the midband fit, intercept, and slope, have also been developed and
successfiffly
used for quantifying tissue properties. Here, QUS methods will be employed to
derive at
least one global parameter that permits the differentiation between vitreo-
retinal disease
and normal aging. The global parameter will ultimately be used to characterize
vitreous
inhomogeneities and diagnose vitreo-retinal diseases at an early state before
outcomes,
such as blindness, become unavoidable.
[0009] In one embodiment, data may be collected using a five-element, 20 MHz,
high-
frequency annular array. The data are collected by transmitting on a single
element of the
array and then the phase-resolved backscatter echo is digitized on all five
elements
simultaneously. By rapidly repeating this process on all five elements, the
transmit-to-
receive echo signals are acquired for all twenty-five possible combinations of
the five-
element array. These transmit-to-receive echoes are then beamformed with a
synthetic-
focusing approach that greatly improves signal to noise, depth of field (DOF)
and
resolution compared to the standard, single-element-transducer method of
current clinical
CA 02906552 2015-09-14
WO 2014/160454
PCT/US2014/026671
ophthalmic ultrasound. Additional information on synthetic-focusing approach
can be
found in co-pending U.S. application number 13/655,086 entitled "SYNTHETIC-
FOCUSING STRATEGIES FOR REAL-TIME ANNULAR-ARRAY IMAGING",
which is incorporated by reference.
[0010] Once data are acquired using an ultrasound approach, a normalization
step is
performed to the raw data in order to remove system and user dependence. The
normalization step requires the use of a well-calibrated ultrasound scattering
phantom
(USP). The phantom consists of spherical mono-dispersed particles of known
size
distribution and known acoustic properties that are randomly and uniformly
located in a
background media of known acoustic properties. Normalization data are acquired
from
the USP using the same system and system settings as those used to acquire
clinical data.
These data are processed and used to remove system and user dependence from
the data
acquired using the ultrasound approach of the present invention. The vitreous
is
segmented out from the surrounding tissue so that the resulting normalized
data only
contain information about the vitreous. The transmission of at least one
ultrasound
signal, the acquisition of backscatter of the transmitted signal and
normalization of the
acquired data results in the creation of one unit. The step of creating one
unit may be
repeated.
[0011] Following normalization, various QUS techniques, as well as common
image
processing methods, are applied to the phase-resolved or envelope-detected
data to
extract clinically relevant local-level region of interest (ROI) estimates and
then global
parameters that relate to scatterer size, scatterer concentration, location
within vitreous,
spatial distribution, etc. Through the scanning and analysis of data from many
patients, a
database of global parameters is compiled of changes related to normal aging
vs. disease-
related changes. In addition to the global parameters obtained from the
ultrasound
backscatter signal, non-ultrasound global parameters that represent clinical
information,
such as age, pre-existing conditions (e.g., myopia), blood sugar level, etc.,
may also be
entered into the database.
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
6
[0012] Using well-known classification methods, the collection of global
parameters can
be combined in different ways to establish a correlation between the global
parameters
and the health/state of the vitreous. Ultimately, at least one global index or
end value can
be employed to diagnose the health of the vitreous, the effect of treatment,
or the
progression of disease. In some embodiments, global parameters could be the
global
index or end value.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. IA shows B-mode imaging of a human subject following posterior-
vitreous
detachment with a conventional single-element 10 MHz probe.
[0014] FIG. 1B shows synthetically focused image of the same eye obtained with
a 20
MHz annular array using monocycle excitation.
[0015] FIGS. IC and 1D show synthetically-focused images obtained with a 20
MHz
annular array using chirp excitation.
[0016] FIGS. 2A to 2C show a macular hole image from optical coherence
tomography,
B-mode ultrasound and a midband-fit QUS parameterization of the raw B-mode
image
data.
[0017] FIGS. 3A to 3D show annular-array images of ex vivo pig eyes into which
blood
had been introduced to simulate vitreous hemorrhage.
[0018] FIGS. 3E and 3F are a B-mode and QUS (midband fit) image examples from
a
human eye scanned with the 20 MHz array.
[0019] FIGS. 4A to 4C show B-mode ultrasonography performed at three positions
(nasal longitudinal, inferotemporal longitudinal and inferotemporal
transverse.
[0020] FIG. 5A shows a sector-scan, ultrasound B-mode image taken at
standardized
settings: (100 total frames acquired at 16 frames/second, 40 mm image depth,
sector scan,
1024x170 pixel image.)
CA 02906552 2015-09-14
WO 2(114/16(1-15-1
PCT/US2014/026671
7
[0021] FIG. 5B shows a first region of interest that includes the entire
vitreous within the
DOF of the ultrasound image.
[0022] FIG. 5C shows a second region of interest that is smaller and entirely
included in
the first region of interest.
[0023] FIGS. 6A to 6C show illustrative scatter plots with best-fit linear
regressions for
three selected cases of Table I.
DESCRIPTION OF THE INVENTION
[0024] The image data required to implement the proposed method to
characterize the
vitreous is not necessarily restricted to a single imaging modality as long as
the modality
can provide a form of raw, time-resolved digitized image information. In one
embodiment ultrasound is used, specifically an annular-array imaging approach
using a
five-element, 20 MHz transducer. Relative to single-element transducers,
annular arrays
provide superior, DOF and resolution. These properties are highly advantageous
for the
detection of inhomogeneities throughout the whole vitreous. The radial
symmetry of the
acoustic field, common acoustic propagation path of all array elements, and
reduction in
system complexity provide significant advantages compared to other ultrasound
approaches. The methods that follow are described as they apply to data
obtained with an
ultrasound method. The approach will provide the first objective means of
characterizing
the vitreous in a quantitative fashion and will represent a powerful tool for
early
diagnosis, monitoring and planning treatment of vitreo-retinal diseases.
[0025] Image-Data Acquisition
[0026] In one embodiment, a real-time, annular-array ultrasound system that
implements
a synthetic-focusing approach is used to acquire data of the vitreous. The
system may
have a lateral scan length of up to 22 mm and operate at real-time frame rates
[Figs. 1 A-
D and 3E]. The transducer may operate at 20 MHz, have five annular elements, a
1 cm
total aperture, and a 31 mm geometric focus. A synthetic-focusing approach
(single
transmit and five receive to acquire all 25 transmit-to-receive combinations)
is used to
CA 02906552 2015-09-14
WO 2(114/16(1-15-1
PCT/US2014/026671
8
simulate the appropriate time delays necessary to focus to some arbitrary
depth. This
method of synthetic-focusing beamforming is more versatile than the more
traditional
dynamic-focusing approach (five transmit and five receive when using a five-
element
annular array) because an arbitrary number of focal zones can be synthesized
with only
five transmit events. The set of 25 acquired transmit-to-receive events can be
reduced for
more efficient processing with minimal loss in image quality. Additional
information on
synthetic-focusing approach can be found in co-pending U.S. application number
13/655,086 entitled "SYNTHETIC-FOCUSING STRATEGIES FOR REAL-TIME
ANNULAR-ARRAY IMAGING", which is incorporated by reference. A further benefit
of the annular array imaging approach is that low contrast vitreous
inhomogeneities, such
as PVD and floaters are better resolved [Figs. 1B-D and 3E] than with current
clinical
imaging approaches [Fig. 1A].
[0027] The ultrasound data digitized from the annular array is saved as raw,
phase-
resolved backscatter echo data sampled at a rate appropriate for the
transducer
bandwidth. The data could be obtained with impulse excitation or coded
excitation (e.g.,
chirp). As is commonly known in the art, coded excitation schemes have the
advantage of
improved penetration depth and sensitivity with only a minimal loss to image
quality.
The data acquired from the eye are typically in a single plane to provide 2D
data. In
one instance, this 2D data represents the full cross section of the globe. By
acquiring 2D
image planes while rotating the imaging probe or translating the probe in the
cross-plane
direction, 3D volumetric data set can also be assembled. The spacing between
image
lines and image planes may be, in one embodiment, less than the acoustic
beamwidth of
the transducer. Various means for mechanically scanning the ultrasound probe
are
possible, although a hand-held approach is most advantageous. An acoustic
coupling
medium will be used between the ultrasound probe and eye.
[0028] An ultrasound annular array has a particular advantage for the proposed
application
because all of the array elements propagate along the same acoustic axis that
minimizes the
chance ofbeamforming errors caused by acoustic refraction. In addition, an
annular array
has a radial acoustic beam profile that provides in plane and out of plane
resolution that
is identical. Finally, the processing of the echo data with delay and sum
synthetic focusing
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
9
results in an averaging of the electronic background noise with a resulting
improvement in
signal contrast. For imaging the vitreous, signal contrast is essential
because the
inhomogeneities are weak scatterers.
[0029] QUS Methods
[0030] Conventional B-mode images are derived from the log-compressed envelope
of
raw phase-resolved backscatter echo data which results in loss of frequency-
dependent
information. QUS methods applied to backscatter echo data, particularly when
the phase
information is retained, represent a robust approach to obtain quantitative
estimates of
acoustical and material properties of tissue in a system- and user-independent
fashion.
[0031] To effectively implement QUS processing, a signal normalization step is
applied
to remove the influence of the transducer, system, and user from the
backscatter echo
signals. This step ensures the QUS methods yield uniform properties as a
function of
depth so that QUS estimates reflect physical changes in scatterer
concentration, size, and
spatial organization rather than system and user factors. A well-calibrated
scattering
phantom that contains known concentrations of mono-disperse scatterers ranging
from 10
to 100 pm (i.e., glass beads or polystyrene spheres) may be used for this step
and the
process is well known in the art. Using the annular array, the backscatter
coefficient is
calculated throughout the phantom, accounting for attenuation, and then fit to
a scattering
model (e.g., Gaussian form factor or a straight-line fit) to yield QUS
estimates. This
process normalizes the backscatter echo data from array such that backscatter
values are
uniform throughout the phantom. Next, backscatter data are obtained from
unknown test
phantoms (i.e., additional phantoms with known scatter sizes and
concentrations).
Because the theoretical backscatter coefficient from the agar phantoms is well-
defined
and easily obtained using Faran theory, the normalized annular-array results
from the
unknown phantom can be compared to and validated against theoretical
predictions. The
annular-array backscatter values can also be compared to those obtained with a
single-
element transducer normalized using the echo from a rigid, planar reflector.
[0032] Before applying QUS methods to characterize vitreous inhomogeneity, the
vitreous is segmented out from surrounding tissue (i.e., sclera, retina, etc.)
The
CA 02906552 2015-09-14
WO 2014/160454
PCT/US2014/026671
segmentation of the vitreous removes the potential contribution from tissue
outside of the
vitreous and allows for the additional calculation of normalized parameters
relative to
vitreous volume or cross-sectional area within each image plane. For example,
a
segmentation approach can be used that uses the generalized Hough transform to
find an
arc of a circle within the 2D images. It is understood that other commonly
used
segmentation approaches could also be used.
[0033] A next step of processing the raw, phase-resolved backscatter is to
calculate QUS
estimates from overlapping (local) regions of interest (ROIs) that are on the
order of 5-20
acoustic wavelengths. The normalized spectrum of the ROI is obtained by
averaging the
spectrum of each echo segment within the ROI and compensating for attenuation
and
system dependence. Then the normalized spectra are fit to a chosen ultrasound
scattering
model (e.g., Gaussian form factor or straight-line fit), and the fit
parameters represent the
QUS estimates. The estimates can be displayed as a parameter image or
converted into a
color map and overlaid back onto a conventional, grey-scale, B-mode image
(Fig. 3F),
but these approaches do not yield a global index or end value of vitreous
health.
However, unlike a B-mode image, the QUS estimates can be related back to
fundamental
tissue properties related to microstructure. Additional QUS estimates can be
derived
from the envelope of the phase resolved backscatter echo data by using
envelope-statistic
models (e.g., Nakagmi, Homodyne-K, etc.). The normalization approach for these
envelope-statistic models differs from that of the backscatter approach,
wherein each
envelope model requires a normalization specific to envelop model.
[0034] QUS-Based Classification Of The Vitreous
[0035] After calculating the local-level ROI estimates from the raw phase-
resolved
backscatter data and/or envelope data, the overall collection of local-level
ROI estimates
can be further processed to derive a collection of clinically relevant global
parameter that
combine and reduce the collection of local-ROI QUS estimates related to
vitreous
inhomogeneities in 2D image planes or a 3D volume derived from 2D image
planes.
Examples of specific quantities to compute are gross size, shape (i.e.,
linear, circular or
focal), location (i.e., close to macula), distribution, and relative
concentration (based on
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
11
dimensional scale, shape, etc.) of inhomogeneities. Because it is not
necessarily possible
to know a priori which parameters are most relevant to a specific vitreo-
retinal disease,
the described approach will generate a diverse set of global parameters. These
can then
be related to age-normal and disease patients after implementing a classifier
analysis.
[0036] Clinically-based, non-ultrasound-based information such as the
standardized NEI
Visual Function Questionnaire (VFQ)-25 or vision contrast sensitivity function
can also
be included for classifier analysis with the set of global parameters. By
working with a
variety of ultrasound and non-ultrasound global parameters, the optimal
combination of
global parameters for characterizing the vitreous can be determined. In this
invention, the
optimal combination of all global parameters for a given eye will be
incorporated into a
classifier in order to yield at least one optimal global index or end value
that is indicative
of overall vitreous pathology. As is well known in the art, it is also
possible to generate
color-coded parameter images that can replace or overlay a standard B-mode
grey scale
image. However, while these images provide quantitative information on a local
level,
they do not provide a global index or end value that represents the state of
the vitreous.
[0037] The diverse set ultrasound and non-ultrasound of parameters will be
used in
conjunction with age-normal patient data to train sophisticated classifiers
(e.g., linear-
discriminant, neural-networks, and support vector-machine approaches) for
detecting and
characterizing inhomogeneity within the vitreous. Support-vector machines
provide the
most flexibility in classifier design at the expense of increased
computational
requirements. These classifiers easily isolate parameters that significantly
contribute to
the characterization of the vitreous and allow for the removal of less
relevant parameters.
After classification analysis, at least one global index or end value that
indicated the state
of the vitreous will be produced.
[0038] Figures 3A-F show an example of local-ROI QUS analysis applied to 20
MHz
annular-array data acquired from an excised pig eye and a human subject using
the
straight-line fit scattering model (i.e., midband and slope parameters). Blood
that
contained an anti-clotting agent (EDTA) (Figs. 3A-C) was injected into the
vitreous of
one pig eye, and clotted blood (Fig. 3D) into another eye. The phase-resolved
backscatter
CA 02906552 2015-09-14
WO 2014/160454
PCT/US2014/026671
12
echo data from the vitreous were analyzed with QUS methods and the local-ROI
QUS
estimates were overlaid onto the B-mode image. The same color range was used
for the
midband cases and the images revealed a difference between the clotted and
unclotted
case. For the midband images, the clotted case had an overall lower magnitude
for the
region of blood than did the unclotted. For the human eye example, the B-mode
image
(Fig. 3E) showed debris in the eye and a PVD. The midband local-ROI QUS
estimates
overlay (Fig. 3F) showed debris in the eye and a differentiation from the
normal vitreous.
Figure 2C shows a similar example of QUS-visualized debris in the vitreous in
a patient
with a macular hole.
[0039] Example 1
[0040] One example of a method to characterize inhomogeneities of the vitreous
is
provided. First, phase-resolved echo data are acquired from planes within the
vitreous
using a 20 MHz, high-frequency-ultrasound annular array. Planar sections are
acquired
in a series of parallel planes such that a 3D volume is sampled. Next, the
data are
normalized and processed to obtain local-ROI QUS estimates. The large
collection of
local-ROI estimates are reduced to a set of global parameters that have
clinical relevance
related to the state of the vitreous. The global parameters along with
relevant non-
ultrasound clinical global parameters obtained from numerous patients are
entered into a
database. The database contains cases of normal vitreous at various ages and
disease
cases. Using the global parameters in the database, a classifier is trained to
distinguish
between healthy vitreous and vitreo-retinal disease. Once the classifier is
trained, a look-
up table can be created such that new global parameters obtained from a
patient with
unknown vitreous state can be used to generate at least one global index or
end value that
indicates whether the vitreous is healthy or diseased. For instance, a
database could be
created from patients with myopia. Global parameters from the new patient may
be
entered in the classifier and analyzed against the myopia database to produce
at least one
global index or end value that would indicate if the vitreous was healthy or
diseased, and
if diseased, the severity or level of progression of myopia.
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
13
[0041] In another exemplary use of the invention, a database of vitreous
parameters from
normal vitreous at various ages is compared to a database of vitreous from
myopes at
various ages to determine if disease is present or progressing. This example
is provided
with reference to an ultrasound approach that detects changes related to
density, speed of
sound and scatterer properties. This example should not be limited to a single
approach,
as other imaging approaches would detect other material properties. For
instance, an
optical technique could detect spectral absorption or scattering from vitreous
inhomogeneities.
[0042] The above example is provided with reference to an ultrasound
backscatter
approach that is sensitive to tissue properties related to density, speed of
sound and
scatterer properties. The invention should not be limited to one ultrasound
imaging
approach or to one imaging modality as other imaging modalities may provide
raw,
phase-resolved information or envelope data related to other material
properties. For
instance, an optical technique could detect spectral absorption or scattering
from vitreous
inhomogeneities.
[0043] Example 2
[0044] In another embodiment of the invention, image-processing methods are
employed
to derive global index or end value of inhomogeneities (floaters) in patients
who are
candidates for vitrectomy. Patients could have developed floater etiologies
related to
posterior vitreous detachment, myopic vitreopathy or other common conditions
of the
eye.
[0045] An ophthalmic, clinical ultrasound unit with a single-element, 15-MHz
transducer with a 20-mm focal length and 7-mm aperture is used to acquire 100
image
frames of log-compressed envelope data before scan conversion and video
display. These
data are digitally sampled at 40-MHz with 8-bit accuracy before envelope
detection. All
the settings on the ultrasound machine are kept the same in order to allow for
direct
comparison between patients. An exam was then performed by placing the
ultrasound
probe directly on the globe at the limbus, to avoid attenuation by the eyelid
and lens and
to minimize trauma to the cornea.
CA 02906552 2015-09-3.4
WO 2(114/16(1-15-1
PCT/US2014/026671
14
[0046] As illustrated in Figs. 4A-C, B-scan ultrasonography is performed at
three
positions (nasal longitudinal, inferotemporal longitudinal and inferotemporal
transverse)
using standardized settings: (100 total frames acquired at 16 frames/second,
40 mm
image depth, sector scan, 1024x170 pixel image; Fig. 5A). For the
inferotemporal scans,
subjects are asked to look supratemporally and inferonasally to induce
vitreous
displacement. The first position, nasal longitudinal, results in a view of the
macula. The
latter two inferotemporal positions provide views of the 1:30 clock hour OD
(right eye)
or 10:30 clock hour OS (left eye). The nasal longitudinal and the two
inferotemporal
positions are referred to as "imac", "trans", and "long", respectively.
[0047] The image stacks of 100 images are manually inspected and only artifact-
free
frames are processed. In this example, the image pixels represent the local-
level ROI
estimates. Within each artifact-free frame, two distinct global-parameter ROIs
are
automatically selected. The first ROI includes the entire vitreous within the
DOF of the
ultrasound image (Fig. 5B). The second ROI is smaller and entirely included in
the first
ROI (Fig. 5C). The global-parameter ROIs are termed whole-central vitreous ROI
and
premacular posterior vitreous ROI, respectively. The whole central vitreous
ROI is
started at a depth of 11.7 mm. The premacular ROI was started at a depth of
19.5 mm.
[0048] Each ROI is processed to yield three distinct global parameters: energy
(E), mean
(M), and P50. E is defined as the sum of the squared acoustic values within
the ROI
divided by the ROI size. M is the mean of the acoustic values divided by the
ROI size.
P50 is obtained by computing the percentage of the ROI filled by clusters of
echogenic
regions greater in size than 50 pixels (0.069 rnm2 ) in this example. The
global
parameters are averaged over the number of artifact-free frames available for
the
corresponding ultrasound data. Normal vitreous is typically hypoechoic and
will yield
low values for the global parameters, whereas floaters are hyperechoic and
will yield
increased values of global parameters.
[0049] After processing, statistical analyses are performed to assess whether
the global
parameters are able to quantify the eye function (i.e., the ability to see
contrast) perceived
by the patient. In this example, the statistical analysis represents the
classifier analysis.
CA 02906552 2015-09-14
WO 2014/160454
PCT/US2014/026671
The contrast sensitivity function (CSF), which represents the relationship
between
contrast sensitivity and spatial frequency, is recorded for each patient and
represents the
patient's subjective evaluation of their floaters on vision function. CSF,
expressed in
%W, typically increases in eyes of patients complaining of vitreous floaters.
Pearson
correlation and associated p values are computed between global parameters and
CSF
value for each eye, scan direction and ROT. Pearson correlation is deemed
significant if
the p value is <0.05. For this study, each eye is treated as independent even
in the case
where two eyes from the same patient are processed. Each eye is also
independently
evaluated for CSF.
[0050] Results
[0051] TABLE 1 displays the Pearson correlations and associated p values for
each
global parameter, scan position and ROT. The results for the whole-central ROI
show that
all correlations but one (P50 in the trans direction) are significant with p
values smaller
than 0.021; the p value obtained for P50 in the trans scan position is just
above 0.05. The
best correlation value is obtained for M in the long position and a slightly
lower value is
obtained for E in the long position. Table I shows that for all QUS estimates,
the
correlation value obtained in the long direction is larger than those obtained
in the other
two scanning directions. For the whole-central ROI, all the remaining
significant
correlation values are between 0.45 and 0.50. The correlation values obtained
for the
premacular posterior ROT are smaller than the corresponding values for the
whole-
vitreous ROI. None of the corresponding p values are below the significance
threshold. In
this example, the whole-central, long-position, M, E, and P50 global
parameters would be
retained as the final global indexes or end values.
[0052] TABLE 1: Pearson correlations and p values for each global parameter,
scan
position and ROI.
E E E M M M P50 P50 P50
imac long trans imac long trans imac -
long trans
Whole-central R 0.49 0.576 0.459 0.471 0.595 0.495 0.472 0.497 0.394
ROI 6
Whole-central p 0.01 0.003 0.021 0.018 0.002
0.012 0.017 - 0.012 0.051
ROI 2
Premacular R 0.37
0.351 0.246 0.364 0.352 0.271 0.352 0.337 0.175
CA 02906552 2015-09-14
WO 2014/160454
PCT/US2014/026671
16
posterior ROI 6
Premacular p 0.06 0.086 0.237 0.074 0.084 0.189 0.085 0.1 0.403
posterior ROI 4
[0053] Figure 6A-C shows illustrative scatter plots with best-fit linear
regressions for
three selected cases of Table I. Figure 6A shows the best correlation result
(0.595 with p
<0.002) obtained for the whole-central ROI. M and the trans position. Overall,
the plots
show a good linear fit, except for two eyes with CSF values > 4.5%W. Figure 68
shows
an intermediate case with a correlation value of 0.496 and p <0.012 obtained
for the
whole-central ROI, E, and the long position. The data points are more
scattered around
the linear regression than in Fig. 6A and the same two eyes with large CSF
values are
also far from the linear regression. Finally, Fig. 6C shows the only non-
significant result
obtained for the whole-central ROI (P50 in the trans position).
[0054] While the present invention has been described in conjunction with
specific
embodiments, those of normal skill in the art will appreciate the
modifications and
variations can be made without departing from the scope and the spirit of the
present
invention. Such modifications and variations are envisioned to be within the
scope of the
appended claims.
